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Introduction: Nursing home residents often have a
high number of comorbidities resulting in
polypharmacy. Inappropriate prescribing is therefore
likely to occur, which in turn is expected to worsen
cognitive impairment, to increase the fall risk and to
decrease residents’ quality of life. The objective of the
‘Discontinuing Inappropriate Medication in Nursing
Home Residents’ (DIM-NHR) study is to examine the
efficacy and cost-effectiveness of the Multidisciplinary
Multistep Medication Review (3MR) that is aimed at
optimising prescribing and discontinuing inappropriate
medication.
Methods: A cluster randomised controlled trial will be
conducted. Elderly care physicians and their wards
(clusters) will be randomised. Data will be collected at
baseline and 4 months after the 3MR has taken place.
Six hundred nursing home residents will be recruited
of whom more than half are expected to suffer from
dementia. The 3MR will be based on consensus
criteria and the relevant literature and will be performed
by the patient’s elderly care physician in collaboration
with a pharmacist.
Analysis: Primary outcomes—the difference in
proportion of residents who successfully discontinued
inappropriate medication between the intervention and
control group at follow-up. Secondary outcomes—
undertreatment, exposure to anticholinergic and
sedative medicines, neuropsychiatric symptoms,
cognitive function, falls, hospital admission, quality of
life and cost-effectiveness.
Ethics and dissemination: Participant burden will
be kept at a minimum. The elderly care physician will
remain free to adjust medication when symptoms
relapse or adverse events occur, rendering serious
adverse events highly unlikely. Study findings will be
published in peer-reviewed journals and a 3MR toolkit
will be developed.
Trial registration number: This study has been
registered at http://www.ClinicalTrials.gov (trial
registration number: NCT01876095)
INTRODUCTION
Nursing home residents are among the frail-
est patient groups. They often have a high
number of comorbidities and are conse-
quently prescribed a high number of medi-
cines. Research suggests that as much as 40%
of prescriptions for nursing home residents
may be inappropriate or suboptimal.1
Inappropriate medication prescribing is com-
monly associated with adverse events, hos-
pital admissions as well as other forms of
unnecessary healthcare utilisation and mor-
tality.2–4 Moreover, a large proportion of
nursing home residents who suffer from
dementia are treated with psychotropic drugs
for neuropsychiatric symptoms. This is
another addition to the drug burden.
Prescribing of medicines is further compli-
cated by pharmacokinetic and pharmacody-
namic changes of the ageing body.1 Thus,
given its magnitude, adverse consequences
and complexity, inappropriate prescribing is
a major challenge to overcome in the care of
nursing home residents. The need to
improve prescribing is therefore urgent.
Hitherto conducted studies, aimed at dis-
continuing inappropriate drug prescribing,
can be classiﬁed into two types. The ﬁrst type
of studies targeted discontinuation of speciﬁc
medicines, whereas the second type exam-
ined sensible discontinuation of an array of
medicines guided by medication reviews.
Evidence from both types of studies suggests
that discontinuation of overprescribed medi-
cation does not necessarily result in declined
health states and may even improve health
outcomes. The ﬁrst type of studies showed,
for instance, that discontinuation of antide-
pressants was tolerated in patients with
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dementia.5 Furthermore, a systematic review of with-
drawal of antihypertensive drugs in elderly patients
showed that 20–85% of the patients remained normoten-
sive, or did not require reinstatement of therapy without
increase in mortality.6 Although there is evidence of the
effectiveness of treating hypertension in older people
who are ﬁt, in the frailer populations overenthusiastic
attempts to lower blood pressure have been associated
with increased mortality and morbidity.7 Another class of
medicines that are worthwhile to discontinue are antipsy-
chotics. Antipsychotics have only limited efﬁcacy for treat-
ment of neuropsychiatric symptoms in patients with
dementia but are associated with considerable side
effects such as accelerated cognitive decline,8 risk of
stroke and death.9 Although discontinuation of antipsy-
chotics is advocated in all guidelines and most discontinu-
ation studies did not ﬁnd a relapse of neuropsychiatric
symptoms,10 one recent study actually found a relapse of
neuropsychiatric symptoms.11 Because of this relapse of
neuropsychiatric symptoms, it may not be possible to dis-
continue antipsychotics for every patient.
The second type of studies has looked at the value of
(multidisciplinary) systematic medication reviews by a
physician in collaboration with a pharmacist. In a small
non-randomised study on discontinuation of multiple
medicines in an Israeli nursing home population, physi-
cians stopped medication in 63% of patients and subse-
quently only 10% of the medicines had to be reinstated.
Mortality and referrals to hospitals signiﬁcantly
decreased and there were savings on drug costs.
Physicians used the so called Good Palliative-Geriatric
Practice algorithm for drug discontinuation as a tool to
guide the medication review process.12 There is some
evidence on the efﬁcacy of medication reviews from
other small and less rigorously conducted studies as well.
And there is also further evidence that multidisciplinary
medication reviews save costs.13 A recent cluster rando-
mised controlled trial (RCT) in nursing homes in
Northern Ireland by Patterson et al14 15 showed that
medication reviews were successful in reducing inappro-
priate psychotropic medication use compared with usual
care and that these were cost-effective as well.
Furthermore, a recent systematic review on medication
reviews and other related interventions to improve pre-
scribing in nursing home residents showed conﬂicting
results.16 However, several studies had methodological
limitations. These included inappropriate outcomes
studied, small sample size and the medication review
being too non-committal as well as the heterogeneity of
the design of medication reviews.15–17 It is therefore dif-
ﬁcult to determine whether the contradicting ﬁndings
reﬂect actual differences between studies or stem from
mere methodological shortcomings. Furthermore, out-
comes such as harm and hospital admission, cognitive
impairment and neuropsychiatric symptoms might be
more convincing, but so far the use of such outcomes
has been limited; or only small effects on these measures
have been found. Moreover, except from the cluster
RCT by Patterson et al,14 little is known about the cost-
effectiveness of systematic medication reviews. Taken
together, there remains a substantial knowledge gap
with respect to the efﬁcacy and cost-effectiveness of sys-
tematic medication reviews, especially in the nursing
home setting.
In our study, systematic medication reviews will be
carried out by the treating elderly care physician in
close collaboration with the pharmacist. These medica-
tion reviews will be aimed at optimising prescribing, in
particular by focusing on discontinuing inappropriate
medication but also by considering undertreatment by
starting appropriate medication that was lacking.
If successful, the intervention will lead to an optimisation
of prescribing in nursing home residents. On the one
hand, the number of medicines the nursing home resi-
dents are taking will be reduced, removing medication
that is no longer necessary or has been prescribed inappro-
priately. This will reduce exposure to anticholinergic and
sedative drug burden (as measured by the Drug Burden
Index (DBI)18—see Methods section) and associated
adverse drug events, harm and number of hospital admis-
sions, neuropsychiatric symptoms and cognitive decline,
possibly increasing nursing home residents’ quality of life,
and will also decrease medication costs. On the other
hand, necessary medication that was actually lacking will
be started. This too has the potential to reduce the
number of hospital admissions, and has thereby the poten-
tial to improve nursing home residents’ quality of life.
As little is known about the views and opinions of the
health professionals, nursing home residents and their
relatives with regard to discontinuing medication in the
nursing home setting, we will also examine their views
and opinions qualitatively while conducting the cluster
RCT. Views and opinions are, for instance, that elderly
care physicians feel pressured by nursing staff to pre-
scribe antipsychotics for behavioural problems in
nursing home residents with dementia.19 Once pre-
scribed, these medications are likely to be continued.20
Also, nursing home residents or their relatives may
object to discontinuing medication because of fear of
return of symptoms or development of withdrawal symp-
toms, but they may also welcome a reduction in the
drug burden. Furthermore, it may be impossible to
involve residents with severe cognitive impairment in
prescribing decisions, but some residents (and their
representatives) may be capable of being involved in
decision-making about medication.21 Together, our
study ﬁndings will provide the rationale for how to opti-
mise prescribing in nursing home residents in order to
attain optimal beneﬁt as well as cost-effectiveness.
Accordingly, the objectives of this study proposal are
(1) to examine whether multidisciplinary medication
reviews effectively optimise prescribing by considering
overprescribing and underprescribing; (2) whether by
doing so, they reduce harm in nursing home residents
and (3) whether multidisciplinary medication reviews
are cost-effective.
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METHODS AND ANALYSIS
A pragmatic cluster RCT will be conducted in a manner
that is consistent with the ‘Consolidated Standards of
Reporting Trials (CONSORT)’ statement (http://www.
consort-statement.org) and the ‘Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT)’ criteria (http://www.spirit-statement.org). In
each participating nursing home, elderly care physicians
and their wards with residents (clusters) will be ran-
domly allocated to the intervention versus control condi-
tion. The intervention condition will consist of the
Multidisciplinary Multistep Medication Review (3MR)
carried out by the patient’s treating elderly care phys-
ician and a pharmacist (see Intervention section). The
control condition consists of usual care including medi-
cation safety monitoring and ad hoc medication reviews
on clinical indication that differs in quality and fre-
quency, but no standardised 3MRs in the manner done
in the intervention condition. Our trial can be consid-
ered a superiority trial as outcomes in favour of the
intervention arm are to be expected. Outcome measures
will be collected at baseline and at 4-month follow-up
after the medication review.
Participants
Our ultimate aim is to enrol ∼600 residents in total (see
below for sample size calculation). Data collection was
started on 1 June 2014 and baseline data have been col-
lected from ∼35 nursing home residents so far. To reach
the target sample size, the researchers will ask for par-
ticipation from a total of 30 wards and will closely
monitor data collection. We estimate that half of the par-
ticipants will have dementia and half will have physically




▸ Long stay wards;
▸ Commitment to perform a 3MR in the manner out-
lined below.
Exclusion criteria
▸ Short stay and revalidation wards because including
these will inﬂate the rate of nursing home residents
who are lost to follow-up.
▸ Specialised wards for an atypical aetiology, for example,
lifespan psychiatric illness or mental disability.
▸ Elderly care physicians who have recently received or
who are to receive recertiﬁcation at short notice with
regard to systematic medication review methodology.
▸ Participation of wards in other studies aimed at




▸ A life expectancy of >4 weeks, as judged by the treat-
ing elderly care physician.
Exclusion criteria
▸ Refusal of treatment with medicines;
▸ Having received a multidisciplinary systematic medica-
tion review in the past 6 months.
Sample size calculation
Sample size calculation is based on the primary
outcome, which is the proportion of residents for whom
≥1 inappropriate medications can be successfully discon-
tinued (see Study parameters section). Based on the lit-
erature and our own pilot studies, we expect ∼20% of
the nursing home residents will have inappropriate
medication successfully discontinued when adopting
usual care. We further expect that this number will
increase to ∼40% after a 3MR in the intervention
group.12 15 22 Assuming 5% signiﬁcance, 80% power and
an intracluster correlation coefﬁcient of 0.1,23 requires
participation by a total of 420 residents or 28 elderly
care physicians (14 in each condition)×15 nursing home
residents. To allow for ∼30% attrition of residents, we
will recruit ∼600 residents or 30 elderly care physicians
times ∼20 residents.
Intervention
The 3MR will be carried out by the elderly care physi-
cians in close collaboration with a pharmacist. It is an
optimised approach for systematic and periodical review-
ing of medication (see table 1). The medication review
process will be piloted by a pharmacist and an elderly
care physician who do not participate in the study.
Rationale for intervention steps
Steps 1 and 2 concerning ‘Patient involvement &
Exploration’ and ‘Drug Reviewing’, respectively (see
table 1), provide a good preparation of the actual medi-
cation review in step 3, the ‘Multidisciplinary Meeting’,
which is essential to let the medication review succeed.17
Moreover, step 1 incorporates the patient perspective.29
We ask the elderly care physician in step 1 to provide
the pharmacist with a list of diagnoses and actual pro-
blems of the nursing home residents. On clinical indica-
tion, the elderly care physician will consult a medical
specialist (neurologist, geriatric psychiatrist, geriatrician,
cardiologist) to verify the diagnoses. In step 2, the
pharmacist will adopt the standardised STOPP and
START criteria to identify potential underprescribing/
misprescribing and overprescribing.24 30 Step 3 is
important in order to attain multidisciplinary consensus
about optimal recommendations, which prevents the
medication review from becoming a mere single direc-
tion advice given by the pharmacist.17 30
Steps 4 and 5, concerning the ‘Pharmacotherapeutical
Action Plan’ and the ‘Implementation & Interim
Evaluation Action Plan’, respectively, are important in
order to initiate action following the medication review,
to facilitate clear communication and mutual feedback
about all arrangements and appointments for the
elderly care physician and a pharmacist, and to involve
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the patient and their representative in the decision
process.27 It is very important that a plan is agreed on
how to monitor the effects of starting, stopping and
changing doses (ie, agree on a scheme of monitoring-
speciﬁc parameters and responsibilities for the monitor-
ing). This will be documented in the action plan. Again
on clinical indication (where necessary and appropriate)
specialists will be consulted.
Study parameters
Main study parameter
The key aim of the 3MR medication reviews is to prevent
overprescribing. Hence, the primary endpoint is the dif-
ference in proportion of residents who successfully dis-
continued inappropriate medication between the
intervention and control group. Successful discontinu-
ation is deﬁned as discontinuation without relapse of
symptoms and without occurrence of withdrawal effects
that make it necessary to restart medication. We oper-
ationalise successful discontinuation of inappropriate
medication as follows: after discontinuation, no new
medication within the same Anatomical Therapeutic
Chemical (ATC) class or for the same indication will be
started at 4-month follow-up (as this would be an indica-
tion of relapse of symptoms or moderate to severe with-
drawal effects).
Secondary study parameters with regard to optimising
prescribing
▸ Starting ≥1 medications that should be started on the
basis of START criteria.16 17
▸ Lowering or increasing of dose.29
▸ The percentage of residents for whom a medication
was replaced by a safer alternative.16 22
▸ Exposure to anticholinergic and sedative medication
as measured with the DBI.18 A higher DBI has been
associated with falls in nursing home residents. We
will calculate the change in DBI scores from baseline
to follow-up using a list of anticholinergic and seda-
tive medication.
Table 1 Overview of Multidisciplinary Multistep Medication Review
Step Time Initiator Label and description
#1 10 min ECP Patient involvement & Exploration
NS Nursing home residents’ experiences and preferences will be assessed by the responsible
member of the NS using a standardised questionnaire. Experiences and preferences of
incapacitated nursing home residents will be assessed through a questionnaire filled out by the
patient’s representative. Furthermore, in preparation of step #2, the ECP will compile the patient’s
diagnoses, allergies and laboratory results. On clinical indication, the ECP will consult a medical
specialist to verify the diagnosis. Subsequently, the ECP will send these data together with the
questionnaire to the P
#2 10 min P Drug Reviewing
The P will review the medication prescribed to the patient to identify both potential
underprescribing using the START criteria24 and overprescribing using the STOPP
criteria,1 2 13 16 17 25 and the Beers criteria.26 An automatic prompt system incorporating the
START & STOPP criteria and Beers criteria will be implemented
#3 10 min ECP Multidisciplinary Meeting
P In a meeting, the ECP and the P will review all information gathered in step #1 and #2.
Subsequently, the information will be reviewed to optimise prescribing (underprescribing/
overprescribing and misprescribing). If the ECP and P cannot determine the right indication for a
medication (the correct diagnosis), the appropriate medical specialist(s), for example, a
cardiologist, a neurologist and a geriatric psychiatrist will be consulted
#4 5 min ECP Pharmacotherapeutical Action Plan
P The ECP and P will register the findings of the review in step #3 in a pharmaceutical action plan27
and, accordingly, the actions that need to be taken, that is, discontinuation, initiation, dose
adjustment, postponing a decision. This plan will also include tapering-off arrangements to prevent
occurrence of withdrawal symptoms if appropriate28 and appointments about the monitoring of
relapse symptoms and withdrawal effects
#5 10 min ECP Implementation & Interim Evaluation Action Plan
NS The ECP and the NS will further implement the pharmaceutical action plan according to the
agreed schedule. To that end, the nursing staff will be clearly informed. The NS will monitor
adverse withdrawal events when discontinuing medication. The ECP will monitor relapse
symptoms. Furthermore, the patient or his or her representative will be informed about the
medication changes to verify possible objections and to clarify that the aim of the intervention is to
improve the care to nursing home residents. In this phase, the elderly care physician will also
document whether a medication had to be reinstated along with the reasons using so-called
trigger lists
ECP, elderly care physician; NS, nursing staff; P, pharmacist.
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Secondary study parameters with regard to patient
outcomes
▸ Quality of life: as measured with the Dementia
Quality of Life Instrument (DQI)31 for patients with
dementia and the European Quality of Life
Questionnaire (EQ-5D-3L), a generic instrument for
patients with no dementia.32 For the DQI and the
EQ-5D-3L, we will calculate the change in scores at
follow-up compared with baseline. The DQI and the
EQ-5D-3L take approximately 5 min to administer.
▸ Harm: fall incidents,1 4 17–19 bone fractures caused by
falling, gastrointestinal bleedings, number of visits to
outpatient clinics and emergency rooms, hospital
admissions, number of visits by medical consultants,
that is, physicians who visit the patients in nursing
homes, total duration of hospital admissions and mor-
tality risk.
▸ Cognitive function: as measured with the change in
scores on the Severe Impairment Battery (SIB) and the
Mini-Mental State Examination (MMSE) at follow-up
compared with baseline. The SIB is a standardised
objective neuropsychological test of cognitive function,
which is speciﬁcally designed for patients with
advanced dementia. We will use the short form that was
developed for nursing home residents33 and validated
for the Netherlands.34 The MMSE is the most widely
used brief instrument to assess cognitive function of
geriatric patients.35 The SIB and the MMSE take
approximately 10 min to administer.
▸ Neuropsychiatric symptoms: as measured with the
change in Neuropsychiatric Inventory (NPI) scores at
follow-up compared with baseline. The NPI is a stan-
dardised rating instrument of neuropsychiatric symp-
toms.36 We will use the NPI-NH, which was developed
and validated for nursing home residents.37 The
NPI-NH takes on average 10 min to administer.
▸ Laboratory results: All biochemical, haematology and
microbiology laboratory examinations that are indica-
tive of organ malfunction and/or recurrence of con-
ditions for which medicines were initially prescribed.
Costs
To enable a cost-effectiveness analysis, all relevant costs
of conducting the medication reviews and healthcare
utilisation will be estimated following the cost-
effectiveness study conducted by Patterson et al.15 Costs
will be based on legal national healthcare and regional
laboratory tariffs and include:
Medication review expenditures
▸ Training of elderly care physician, nursing staff and
pharmacist.
▸ Salary costs of elderly care physician, nursing staff
and pharmacist involved with carrying out the medi-
cation reviews including implementation by elderly
care physician.
Healthcare utilisation expenditures
▸ Salary costs: medical consulting time estimated from
the patient’s medical status including consultations by
elderly care physicians, all other physicians including
medical consultants and other paramedical care pro-
fessionals (physiotherapist, speech and language ther-
apist, acoustician, optometrist, dentist, dietitian,
specialised nurse, pharmacist, podiatrist and nursing
home psychologist).
▸ Medication costs: of all medication prescribed.
▸ Laboratory examinations: of all biochemical, haematol-
ogy and microbiology laboratory examinations.
▸ Additional costs: of total duration and number of visits
to emergency room, outpatient clinics and hospital
admissions.
Covariates
Covariates at the nursing home level as well as on the
nursing home resident’s level will be measured and
include:
Nursing home characteristics
Prescribing information, type of ward (for nursing
home residents with dementia vs those with physically
disabling conditions) and number of residents per ward.
Elderly care physicians
▸ Number of years of working experience as physician
in the ﬁelds of elderly care, geriatrics and geriatric
psychiatry.
▸ Amount of training with regard to geriatric pharma-
cotherapy, clinical pharmacology, polypharmacy,
inappropriate prescribing and medication review
methodology.
Nursing home residents’ characteristics
▸ Demographic characteristics: sex, age, educational level,
marital status.
▸ Clinical characteristics: length of stay in nursing home,
number of prescribed medicines, medical conditions
and a revised Charlson’s comorbidity index.38
Randomisation, blinding and intervention allocation
Randomisation will occur at the level of the elderly care
physician and his or her ward such that half of the elderly
care physicians will be randomly assigned to perform the
3MR (the intervention condition) and half will perform
usual care (the control condition). This will be done to
avoid cross-contamination. Randomisation will be per-
formed by one of the researchers who is not involved in
collecting the data from participants. Because of the rela-
tively small number of elderly care physicians (N=30),
they will be matched ﬁrst on relevant characteristics
including supplying pharmacy, healthcare organisation,
type of ward(s) (for residents with dementia vs those with
physically disabling conditions or both), and number of
residents of their ward(s). Based on this matching pro-
cedure, pairs of elderly care physicians who are most
alike will be made. Subsequently, within each pair, one
physician will be randomly assigned to the intervention
condition and one physician will be randomly assigned to
the control condition.39 Random assignment will be
established using the random variable function of SPSS.
As clinicians will perform the 3MR medication review,
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they cannot be kept blind to the patient’s allocation to
the experimental condition (receiving the medication
review) versus the control condition (usual care).
Nursing home residents, their legal representatives and
assessors of the study parameters will, however, be kept
blind to intervention allocation as far as possible. The
study is therefore a single blind study.
Quality of data collection
Data will be collected in a standardised manner using
data collection forms. A trained neuropsychologist will
assess residents’ cognitive function using objective and
validated neuropsychological tests (see above ‘Study para-
meters’ section). Neuropsychiatric symptoms and quality
of life will be assessed by a member of the staff using vali-
dated questionnaires (see above ‘Study parameters’
section). To counteract occurrence of missing data, com-
pleteness of data for each individual resident will be mon-
itored using standardised progress forms. Follow-up data
will be collected 4 months later. Although this is relatively
soon, this will be done because of the high mortality and
morbidity risk of nursing home residents. Data will be
entered twice by two research assistants in two independ-
ent data ﬁles. Discrepancies between the ﬁles will be
checked against hardcopy and source data and errors will
be corrected accordingly.
Statistical analysis
Descriptive results will be presented at the patient and
the ward level. Potential bias will be examined in the fol-
lowing respects. First, a non-response analysis will be per-
formed to examine whether male or female and
younger or older residents were more likely to partici-
pate. Second, extent of differential attrition will be
assessed by examining whether residents who were lost
to follow-up signiﬁcantly differed on baseline character-
istics from residents who were retained at follow-up.
Successful discontinuation of inappropriate medication
and secondary study parameters will be treated as
dependent variables in generalised linear mixed models.
This type of analysis will be employed to account for
dependence of data (nursing home residents within
wards). To that end, a random intercept and a random
slope at the level of wards will be entered into the linear
mixed model. If randomisation is successful, no adjust-
ment for covariates will be necessary. In that case, only
the effect of condition (intervention versus control con-
dition) will be examined. Consistency of ﬁndings will be
assessed with sensitivity analyses. First, we will adopt an
intention-to-treat approach in which nursing home resi-
dents who underwent a medication review but who were
lost to follow-up will be included in the analysis and
counted as if medicines could not be successfully
stopped (‘intention to treat’). Second, in a per-protocol
analysis, we will include only those nursing home resi-
dents who actually received the intervention and who
have complete data. All statistical tests will be one sided.
p Values ≤5% will be considered signiﬁcant.
Cost-effectiveness analysis
The cost-effectiveness of the 3MR will be examined by
calculating the Incremental Cost Effectiveness Ratio
(ICER). Two different ICERs will be calculated. The ﬁrst
ICER will reﬂect the difference in the mean costs
(in US$) between the intervention and control group
divided by the difference in the percentage of residents
who successfully discontinue medication in the interven-
tion and control group. The second ICER will reﬂect
the difference in the mean costs (in US$) between the
intervention and control group divided by the difference
in estimated quality-adjusted life-years (QALYs) in the
intervention and control group. QALYs will be estimated
using the utilities of health states on the DQI on base-
line and follow-up. Uncertainty in the point estimate of
the ICER will be investigated using 95% CIs obtained
with non-parametric bootstrapping.
Study procedures
The ﬂow chart of ﬁgure 1 provides a schematic overview
of the study phases along with the participant ﬂow, for
example, how many participants decline participation or
are lost to follow-up. Different wards will participate in a
sequential manner to the study.
ETHICS AND DISSEMINATION
The study will be conducted in accordance with the
Declaration of Helsinki regarding the Ethical Principles
for Medical Research Involving Human Subjects
(amended by the 64th World Medical Association’s
General Assembly, Fortaleza, Brazil, October 2013). All
nursing home residents will be asked to provide written
informed consent (IC). In case a resident is incapaci-
tated, her or his legal representative will be asked to
consent instead. Regardless of IC, signs expressed by
nursing home residents, which might be indicative of
objection, will be carefully monitored and will be
deemed an instant reason for discontinuation of testing.
Furthermore, after careful weighting of the beneﬁts
and harms, we are conﬁdent that systematic medication
reviews have much potential for nursing home residents
(as outlined above). At the same time, the risk of occur-
rence of (serious) adverse events related to study partici-
pation will be deemed highly unlikely. Systematic
medication reviews will be carried out by the treating
elderly care physician and the pharmacist and the ﬁnal
responsibility to make deﬁnite treatment decisions will
rest with the treating elderly care physician.
Data will be conﬁdentially handled and stored. To
assure conﬁdentiality, research data and residents’ per-
sonal data will be stored in two different ﬁles. Data
records from both ﬁles will be linked with an identiﬁca-
tion number that cannot be traced to the individual resi-
dents and their personal characteristics, for example,
year of birth. The ﬁle with residents’ personal data will
be password protected and will be safeguarded by the
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investigators. To avoid scientiﬁc fraud or misconduct, all
investigators will have full access to the data.
Finally, study results will be published in peer-reviewed
journals and in relevant news channels for clinicians.
In addition, this study has been registered at http://
www.ClinicalTrials.gov (trial registration number:
NCT01876095). Duplicate publication will be avoided.
In addition to publication of study results, a practical
toolkit will be constructed to carry out the 3MR medica-
tion reviews.
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